Genmab — Juli 2024
-
Kort video: Sommerpanik på aktiemarkederne https://proinvestor.com/boards/121481
-
Genmabs kræfthåb viser fortsat solide vækstrater https://proinvestor.com/investornyt/1190236/genmabs-kraefthab-viser-fortsat-solide-vaekstrater
-
ADS i usa stiger med 1% - svarende til den danske notering..
-
Torsdagens aktier: Genmab skilte sig positivt ud i presset C25 https://proinvestor.com/investornyt/1190286/torsdagens-aktier-genmab-skilte-sig-positivt-ud-i-presset-c25
-
@Pensionisten med 1% stigning i US. så får jeg kursen til 1930dkr
-
Epkinly $17/27/63 mln i hhv Q4/Q1/Q2 jf https://proinvestor.com/investornyt/1190236/genmabs-kraefthab-viser-fortsat-solide-vaekstrater - det tegner godt

-
https://investors.abbvie.com/static-files/81a1993c-c366-44dc-89d7-106c21327573 p43. Abbvie in 2023: collaboration revenue $28 mln and International $3 mln.
-
https://investors.abbvie.com/static-files/c9936258-3a4c-48f0-968b-6d533ead6dee p7. If we take 3 month “revenue” data 14+22=36 then I belive real Epkinly revenue could be 31+32=63 (US+RW=Total) and the souce could right. My estimate is 45% of US revenue as collaboration revenu and Japan 8 mln out of the 22 mln recorded by Abbvie. If its true Genmab should record $38-40 mln in Q2 as Epkinly revenue. But hope we somewhere will get the revenue figures more easy

-
you have to start dialing a Danish phone number now if
you want Trial Information on PRO1184
https://www.clinicaltrials.gov/study/NCT05579366?tab=history&a=16&b=17#version-content-panel
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind